Sign Up
Stories
Exclusive License for Velphoro® in China
Share
Growing Markets for Pain Relief
Mineralys Therapeutics to Present at Bio...
Transplant and Kidney Function: Positive...
ANJESO Drug Insight and Market Forecast
Aligos Therapeutics Financial Disclosure
Alpha-1 Antitrypsin Deficiency Epidemiol...
Overview
API
China Medical System Holdings Limited has secured an exclusive license for the sucroferric oxyhydroxide chewable tablets Velphoro® in several Chinese regions, benefiting from the approval of the product for controlling serum phosphorus levels in chronic kidney disease patients.
Ask a question
How does the approval of Velphoro® in multiple regions contribute to the broader healthcare landscape in China?
How might the exclusive license for Velphoro® impact the competitive landscape in the kidney disease treatment market in China?
What are the potential economic implications for China Medical System Holdings Limited and its investors with this exclusive license?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage